Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar RangeSeeking Alpha • 01/22/24
Crispr Wins Its Second Gene-Editing Approval In Another Boost To Vertex StockInvestors Business Daily • 01/16/24
CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta ThalassemiaGlobeNewsWire • 01/16/24
What Does It Mean for Investors if CRISPR Therapeutics Gets Bought Out in 2024?The Motley Fool • 01/14/24
CRISPR Therapeutics AG (CRSP) 42nd Annual J.P. Morgan Healthcare Conference (Transcript)Seeking Alpha • 01/10/24